ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years
Anupriya Singhal
Matched on ORCID iD 0000-0001-8816-0065; OpenAlex author ID A5024898449; NIH RePORTER profile ID 78318161. Sources: funder_awards.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 3
- Labs led
- 1
- Collaborators
- 32
2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 2 papers, 1 grant · 2026: 2 papers, 2 grants
Papers 7
- Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Co-author DOI 10.1038/s41591-026-04299-5↗
- Pancreatic Cancer: Translating Tumor Biology into Actionability. Co-author DOI 10.1158/2159-8290.cd-25-2014↗
- Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort. Co-author DOI 10.1093/jnci/djae269↗
- Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf139↗
- Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease. Co-author DOI 10.1093/jnci/djae095↗
- A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-24-0740↗
- Systematic Comparison of Pancreatic Ductal Adenocarcinoma Models Identifies a Conserved Highly Plastic Basal Cell State. Co-author DOI 10.1158/0008-5472.can-22-1742↗
Grants 3
- Defining epigenetic drivers of cell-state plasticity in pancreatic cancer AWARD pancan:2026-anupriya-singhal-md-phd-defining-epigenetic-drivers-of-cell-stat
- Defining epigenetic drivers of cell-state plasticity in pancreatic cancer K08CA308851↗
- Interrogating vulnerabilities of a KRAS inhibitor-resistant cell state in pancreatic cancer AWARD lustgarten:2025-anupriya-singhal-md-phd-interrogating-vulnerabilities-of-a-kras-
Closest collaborators
The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Wungki Park · 4 shared papers, 2024–2026 · strength 0.83
- Paper Pancreatic Cancer: Translating Tumor Biology into Actionability. DOI 10.1158/2159-8290.cd-25-2014↗
- Paper Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. DOI 10.1093/jnci/djaf139↗
- Paper Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated… DOI 10.1093/jnci/djae095↗
- Eileen Mary O'Reilly · 4 shared papers, 2024–2026 · strength 0.83
- Paper Pancreatic Cancer: Translating Tumor Biology into Actionability. DOI 10.1158/2159-8290.cd-25-2014↗
- Paper Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. DOI 10.1093/jnci/djaf139↗
- Paper Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated… DOI 10.1093/jnci/djae095↗
- Fiyinfolu O. Balogun · 4 shared papers, 2024–2026 · strength 0.83
- Paper Pancreatic Cancer: Translating Tumor Biology into Actionability. DOI 10.1158/2159-8290.cd-25-2014↗
- Paper Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. DOI 10.1093/jnci/djaf139↗
- Paper Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated… DOI 10.1093/jnci/djae095↗
- Marinela Capanu · 3 shared papers, 2024–2025 · strength 0.53
- Paper Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. DOI 10.1093/jnci/djaf139↗
- Paper Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated… DOI 10.1093/jnci/djae095↗
- Paper Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a larg… DOI 10.1093/jnci/djae269↗
- Anna M. Varghese · 3 shared papers, 2024–2025 · strength 0.53
- Paper Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. DOI 10.1093/jnci/djaf139↗
- Paper Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated… DOI 10.1093/jnci/djae095↗
- Paper Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a larg… DOI 10.1093/jnci/djae269↗
- Fergus Keane · 3 shared papers, 2024–2025 · strength 0.53
- Paper Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. DOI 10.1093/jnci/djaf139↗
- Paper Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated… DOI 10.1093/jnci/djae095↗
- Paper Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a larg… DOI 10.1093/jnci/djae269↗
- Darren Cowzer · 3 shared papers, 2024–2025 · strength 0.53
- Paper Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. DOI 10.1093/jnci/djaf139↗
- Paper Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated… DOI 10.1093/jnci/djae095↗
- Paper Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a larg… DOI 10.1093/jnci/djae269↗
- Kenneth H. Yu · 3 shared papers, 2024–2025 · strength 0.53
- Paper Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. DOI 10.1093/jnci/djaf139↗
- Paper Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated… DOI 10.1093/jnci/djae095↗
- Paper Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a larg… DOI 10.1093/jnci/djae269↗
- Kevin C. Soares · 2 shared papers, 2025–2026 · strength 0.47
- Christine A. Iacobuzio–Donahue · 2 shared papers, 2022–2026 · strength 0.43
- Fionnuala Crowley · 2 shared papers, 2025 · strength 0.36
- Alice Chia-Chi Wei · 2 shared papers, 2025 · strength 0.36
- Rona D. Yaeger · 2 shared papers, 2024 · strength 0.34
- Marsha Reyngold · 1 shared paper, 2026 · strength 0.30
- Mara H. Sherman · 1 shared paper, 2026 · strength 0.30
- Olivera Grbovic-Huezo · 2 shared papers, 2022–2024 · strength 0.29
- Tuomas Tammela · 2 shared papers, 2022–2024 · strength 0.29
- Lily V. Saadat · 1 shared paper, 2025 · strength 0.19
- Vinod P. Balachandran · 1 shared paper, 2025 · strength 0.17
- Ghassan K. Abou‐Alfa · 1 shared paper, 2025 · strength 0.17
- T. Peter Kingham · 1 shared paper, 2025 · strength 0.17
- Michael Ian D'Angelica · 1 shared paper, 2025 · strength 0.17
- Jeffrey A. Drebin · 1 shared paper, 2025 · strength 0.17
- David Paul Kelsen · 1 shared paper, 2025 · strength 0.17
- William R. Jarnagin · 1 shared paper, 2025 · strength 0.17
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.